19.01.2011 • News

Amgen To Sell California Drug Plant To Boehringer

Amgen, the world's biggest maker of biotechnology drugs, plans to sell its Fremont, Calif., development and manufacturing plant to Germany's Boehringer Ingelheim, the companies said on Tuesday. Financial terms were not disclosed.

Amgen, based in Thousand Oaks, Calif., said the 100,000-square-foot plant employs about 360 people who will become employees of Boehringer.

The German company, which has manufactured Amgen drugs on a contract basis for more than 10 years, said the deal will allow it to expand contract manufacturing, process development and development of active ingredients based on biologics.

The deal is expected to close in March.

Amgen obtained the Fremont facility in its 2006 acquisition of antibody drug maker Abgenix.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Book

Innovation Management in Sustainable Chemistry

Innovation Management in Sustainable Chemistry

Comprehensive resource on sustainable chemistry, bridging the skill gap between academic science education and innovation and entrepreneurship

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.